Skip to main content

Market Overview

Maxim Still Calling For 900% Upside At StemCells After Latest Phase II Data


Dr. Stephen Huhn, CMO of StemCells Inc (NASDAQ: STEM) provided additional details regarding the ongoing Phase II Pathway Study in chronic cervical spinal cord injuries at the annual meeting of the American Spinal Injury Association on April 15.

Maxim’s Jason Kolbert maintained a Buy rating on the company, with a price target of $3.

Cohort I Results

Kolbert mentioned that the presentation by Dr. Huhn “included a top line update for the six patients enrolled in open label Cohort I from the Pathway Study.”

The analyst went on to say that the six-month results from the Cohort I trial revealed improvement in muscle strength in five of the six patients, with improved performance on functional tasks being demonstrated by four of these five patients.

“In addition, four of the six patients had improvement in the level of cord injury,” Kolbert stated.

StemCells expects to announced details of the final 12 month results for Cohort I later during the quarter.

The Positives

If the company’s HuCNS-SC cells work “even moderately,” Kolbert believes that it could prove to be a “blockbuster”, given that the market is large, with significant upside possible for StemCells.

Kolbert expects the company to provide definitive proof of concept over the next 12 to 18 months.

Latest Ratings for STEM

May 2021Goldman SachsInitiates Coverage OnBuy
May 2016Maxim GroupDowngradesBuyHold
Apr 2016Rodman & RenshawAssumesBuy

View More Analyst Ratings for STEM
View the Latest Analyst Ratings


Related Articles (STEM)

View Comments and Join the Discussion!

Posted-In: Jason Kolbert Maxim GroupAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas

Latest Ratings

NTNXMorgan StanleyMaintains41.0
VLORaymond JamesMaintains100.0
MPMorgan StanleyMaintains37.5
PSXRaymond JamesMaintains101.0
CNTAMorgan StanleyInitiates Coverage On37.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at